Syntax Research Inc. Has $200,000 Stake in Abbott Laboratories $ABT

Syntax Research Inc. lowered its stake in Abbott Laboratories (NYSE:ABT) by 81.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,200 shares of the healthcare product maker’s stock after selling 9,800 shares during the quarter. Syntax Research Inc.’s holdings in Abbott Laboratories were worth $200,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. J. Stern & Co. LLP raised its stake in Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after acquiring an additional 39,005,451 shares during the period. Norges Bank acquired a new stake in Abbott Laboratories during the fourth quarter worth approximately $2,938,892,000. Bank of America Corp DE bought a new position in shares of Abbott Laboratories in the second quarter worth $1,603,607,000. Legal & General Group Plc acquired a new position in shares of Abbott Laboratories in the 2nd quarter valued at approximately $1,082,524,000. Finally, Flossbach Von Storch SE bought a new stake in Abbott Laboratories during the second quarter worth $902,938,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $108.29 on Monday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The firm’s 50 day moving average is $104.43 and its 200 day moving average is $100.03. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $187.38 billion, a P/E ratio of 35.05, a PEG ratio of 2.01 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s payout ratio is currently 81.55%.

Analysts Set New Price Targets

A number of brokerages have recently commented on ABT. Robert W. Baird began coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target for the company. BTIG Research increased their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Royal Bank Of Canada reissued an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a research note on Friday, July 17th. Piper Sandler reissued an “overweight” rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, TD Cowen boosted their price target on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, August 25th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $119.50.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.